[1] TAN S Z, LI D P, ZHU X. Cancer immunotherapy:pros, cons and beyond[J]. Biomed Pharmacother, 2020, 124:109821.
[2] QIN S, XU L P, YI M, et al. Novel immune checkpoint targets:moving beyond PD-1 and CTLA-4[J]. Mol Cancer, 2019, 18(1):155.
[3] CORTEZ M A, ANFOSSI S, RAMAPRIYAN R, et al. Role of miRNAs in immune responses and immunotherapy in cancer[J]. Genes Chrom Cancer, 2019, 58(4):244-253.
[4] ZHANG Y, TANNO T, KANELLOPOULOU C. Cancer therapeutic implications of microRNAs in the regulation of immune checkpoint blockade[J]. ExRNA, 2019, 1(1):19.
[5] WIGHTMAN B, HA I, RUVKUN G. Posttranscriptional regulation of the heterochronic gene lin-14 by lin-4 mediates temporal pattern formation in C. elegans[J]. Cell, 1993, 75(5):855-862.
[6] LIN S B, GREGORY R I. MicroRNA biogenesis pathways in cancer[J]. Nat Rev Cancer, 2015, 15(6):321-333.
[7] FROMM B, BILLIPP T, PECK L E, et al. A uniform system for the annotation of vertebrate microRNA genes and the evolution of the human microRNAome[J]. Annu Rev Genet, 2015, 49:213-242.
[8] FRIEDMAN R C, FARH K K H, BURGE C B, et al. Most mammalian mRNAs are conserved targets of microRNAs[J]. Genome Res, 2009, 19(1):92-105.
[9] KALAYINIA S, ARJMAND F, MALEKI M, et al. MicroRNAs:roles in cardiovascular development and disease[J]. Cardiovasc Pathol, 2021, 50:107296.
[10] ARDIZZONE A, CALABRESE G, CAMPOLO M, et al. Role of miRNA-19a in cancer diagnosis and poor prognosis[J]. Int J Mol Sci, 2021, 22(9):4697.
[11] DI LEVA G, GAROFALO M, CROCE C M. MicroRNAs in cancer[J]. Annu Rev Pathol, 2014, 9:287-314.
[12] VENTURA A, JACKS T. MicroRNAs and cancer:short RNAs go a long way[J]. Cell, 2009, 136(4):586-591.
[13] ZHANG X W, SCHWARTZ J C D, GUO X L, et al. Structural and functional analysis of the costimulatory receptor programmed death-1[J]. Immunity, 2004, 20(3):337-347.
[14] MCDERMOTT D F, ATKINS M B. PD-1 as a potential target in cancer therapy[J]. Cancer Med, 2013, 2(5):662-673.
[15] LATCHMAN Y, WOOD C R, CHERNOVA T, et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation[J]. Nat Immunol, 2001, 2(3):261-268.
[16] TANG D L, LOTZE M T. Tumor immunity times out:TIM-3 and HMGB1[J]. Nat Immunol, 2012, 13(9):808-810.
[17] MENG W, YE Z Q, CUI R, et al. MicroRNA-31 predicts the presence of lymph node metastases and survival in patients with lung adenocarcinoma[J]. Clin Cancer Res, 2013, 19(19):5423-5433.
[18] YANG L, JIANG J S. GAS5 regulates RECK expression and inhibits invasion potential of HCC cells by sponging miR-135b[J]. Biomed Res Int, 2019, 2019:2973289.
[19] ZHANG J Q, ZHU Y, HU L S, et al. MiR-494 induces EndMT and promotes the development of HCC (hepatocellular carcinoma) by targeting SIRT3/TGF-β/SMAD signaling pathway[J]. Sci Rep, 2019, 9(1):7213.
[20] GUARINO M, CAPORASO N, MORISCO F. Liver resection is always a good choice for hepatocellular carcinoma (HCC) patients regardless of Barcelona Clinic Liver Cancer (BCLC) stage:the therapeutic hierarchy[J]. Ann Transl Med, 2020, 8(20):1282.
[21] BATISTA P J, CHANG H Y. Long noncoding RNAs:cellular address codes in development and disease[J]. Cell, 2013, 152(6):1298-1307.
[22] MORRISON A H, BYRNE K T, VONDERHEIDE R H. Immunotherapy and prevention of pancreatic cancer[J]. Trends Cancer, 2018, 4(6):418-428.
[23] ASHIZAWA M, OKAYAMA H, ISHIGAME T, et al. miRNA-148a-3p regulates immunosuppression in DNA mismatch repair-deficient colorectal cancer by targeting PD-L1[J]. Mol Cancer Res, 2019, 17(6):1403-1413. |
